Dry Eye Syndrome Market Canvassed in Insightful GlobalData Report Recently Published at MarketPublishers.com
18 Feb 2016 • by Natalie Aster
LONDON – The market for dry eye syndrome (DES, also termed keratoconjunctivitis sicca) has been led by artificial tears therapy and by Restasis Ophthalmic (in the USA) over a number of years, with few approved therapeutic options currently avaialble in the 9MM – the USA, 5EU, Japan, China and India. Novel classes of drugs are expected to the reach the market over the coming years. Specifically, the major stimulator of growth of the DES market growth will likely be the launch of first-in-class drugs. The change in the therapeutic landscape has already been noticed with Ikervis’ arrival in Europe as of 2015. Moreover, additional marketing approvals are being sought for currently marketed Restasis and Diquas in new countries in the 9MM. DES’s current late-stage pipeline is diverse, with first-in-class drugs in development with novel modes of action.
However, the market development has been hindered by a range of factors, with the most significant growth barrier being a vast number of drugs failing in late-stage clinical trials.
The introduction of novel therapies across the 9MM is poised to improve treatment rates and offer alternative options for a great many patients.
The hugest unmet need in the DES marketplace is projected to remain the dearth of additional efficacious and safe therapeutic agents with novel modes of action. Additionally, simplifying dosing regimens is an essential consideration for firms engaged in the development of drug products to treat these patients.
Herantis, Alcon, Mimetogen, Allergan, Otsuka, RegeneRx, Mitotech, Santen and Shire are the leading players in the marketplace.
Insightful research report “PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024” created by GlobalData provides an in-depth evaluation of the world DES marketplace. It gives an overview of the disease, shedding light on epidemiology, etiology, pathophysiology, symptoms, diagnosis, etc. The report provides yearly market revenues, annual treatment cost and treatment usage pattern data from 2014 plus forecasts to 2024. The report reveals the unmet needs, offers an assessment of R&D activities and clinical trials, offers an analysis of late-stage clinical trials as well as unveils the implications for the glaucoma therapeutics market. The report focuses on the 4 late-stage pipeline DES drug products examining emerging trends and an overview of drugs in early-stage development. The research study canvasses the current and future market competition in the worldwide DES therapeutics market. A comprehensive review of the key industry growth restraints, driving factors and challenges is also available.
PharmaPoint: Dry Eye Syndrome - Global Drug Forecast and Market Assessment to 2024
Published: November, 2015
Price: US$ 10,995.00
More reports by this publisher can be found at GlobalData page.